|
MechanismACVR2B inhibitors |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
100 Clinical Results associated with Santa Maria Biotherapeutics, Inc.
0 Patents (Medical) associated with Santa Maria Biotherapeutics, Inc.
100 Deals associated with Santa Maria Biotherapeutics, Inc.
100 Translational Medicine associated with Santa Maria Biotherapeutics, Inc.